Tech Center 1600 • Art Units: 1651 1653
This examiner grants 31% of resolved cases
Natalie M Moss is an examiner in Tech Center 1600 and Art Unit 1651. She has 523 resolved cases, with an allowance rate of 30.8 percent. The median days to allowance is 1414. These figures indicate a challenging environment for applicants and a long timeframe for prosecution in this unit.
The interview lift is 17.1 percent, showing that interviews can help improve the odds of success. Even with a 30.8 percent allowance rate, an interview provides a 17.1 percent increase in the likelihood of allowance. Practitioners should consider this lift as a way to overcome the difficulties indicated by the baseline metrics.
The 523 resolved cases provide a solid statistical foundation for Art Unit 1651. The 1414 day median and allowance rate are critical for planning. The interview lift is a valuable data point for those seeking to optimize their prosecution strategy and manage client expectations regarding the likely outcome.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 14239690 | PROCESS FOR PRODUCING CELLULASES USING A FILAMENTOUS FUNGUS SUITABLE FOR A FERMENTER, HAVING A LOW VOLUMETRIC OXYGEN TRANSFER COEFFICIENT KLA | Non-Final OA | IFP ENERGIES NOUVELLES |
| 17602458 | CELL CULTURE MEDIA COMPRISING KETO ACIDS | Non-Final OA | MERCK PATENT GMBH |
| 17964325 | METHOD FOR MEDIUM TREATMENT BEFORE INOCULATION | Non-Final OA | Genentech, Inc. |
| 18227801 | Methods for Antimicrobial Susceptibility Testing | Final Rejection | The Regents of the University of California |
| 18237744 | NANOFIBER-HYDROGEL COMPOSITES FOR CELL AND TISSUE DELIVERY | Non-Final OA | The Johns Hopkins University |
| 17439251 | ISOLATION, ENRICHMENT AND EXPANSION OF CONE PROGENITOR CELLS AND USES THEREOF | Non-Final OA | Massachusetts Institute of Technology |
| 17914691 | METHODS OF USING UMBILICAL CORD PRODUCTS FOR TREATMENT OF OCULAR SURFACE DISORDERS | Non-Final OA | BIOTISSUE HOLDINGS INC. |
| 17879015 | Method of Recovering Nitrogen and Sulfur Resources Through Anaerobic Fermentation | Final Rejection | SK Innovation Co., Ltd. |
| 17541558 | FASTING MIMICKING KETOGENIC DIET (FMD) TO PROMOTE SKELETAL MUSCLE REGENERATION AND STRENGTH | Final Rejection | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 18359053 | METHOD FOR PROMOTING PROLIFERATION AND PLURIPOTENCY FACTOR EXPRESSION OF STEM CELLS AND COMPOSITION PRODUCED USING THE SAME | Final Rejection | BUDDHIST TZU CHI MEDICAL FOUNDATION |
| 18648537 | COMPOSITION FOR CELL ADDITION | Non-Final OA | AGC INC. |
| 17180189 | METHOD FOR DETECTION AND ANALYSIS OF CEREBROSPINAL FLUID ASSOCIATED UBE3A | Non-Final OA | University of South Florida |
| 18258403 | BLOOD SAMPLER CONTAINING ANTI-PLATELET AGENT AND WATER-SOLUBLE MATRIX MATERIAL | Non-Final OA | Radiometer Medical ApS |
| 18605672 | SYSTEMS AND METHODS FOR EX VIVO ORGAN CARE | Non-Final OA | TransMedics, Inc. |
| 17995138 | STABILIZING COMPOSITION AND METHOD FOR PRESERVING A BODILY FLUID | Final Rejection | DNA Genotek Inc. |
| 14398210 | DOSING REGIMENS FOR THE TREATMENT OF POMPE DISEASE | Non-Final OA | Amicus Therapeutics, Inc. |
| 16467358 | DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY | Non-Final OA | St. Jude Children's Research Hospital |
| 17755834 | FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE | Final Rejection | FIGENE, LLC |
| 16519384 | Method of Producing a Mycological Product and Product Made Thereby | Final Rejection | Ecovative LLC |
| 17610894 | METHOD FOR REDUCING METHIONINE OXIDATION IN RECOMBINANT PROTEINS | Non-Final OA | FORMYCON AG |
| 17435911 | METHOD FOR DETERMINING EFFICACY | Non-Final OA | LDN Pharma Limited |
| 17259784 | INJECTION TECHNIQUES FOR THE TREATMENT OF CELLULITE | Non-Final OA | ENDO OPERATIONS LIMITED |
| 16690197 | Novel methods for delivering therapeutics agents to the eye via the nasal passages | Non-Final OA | Noveome Biotherapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy